Caribou Biosciences (CRBU) Cash & Equivalents (2020 - 2026)

Caribou Biosciences (CRBU) has reported Cash & Equivalents for 7 consecutive years, with $12.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 59.01% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $12.1 million (down 59.01% YoY), while the FY2025 annual figure was $12.4 million, down 24.14% from the prior year.
• Cash & Equivalents slipped to $12.1 million in Q1 2026 per CRBU's latest filing, from $12.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $147.6 million in Q1 2022 and bottomed at $11.1 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $52.9 million across 5 years, with a median of $49.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 81.14% — and 2023, when it grew 26.77%.
• Caribou Biosciences' Cash & Equivalents stood at $58.3 million in 2022, then declined by 12.3% to $51.2 million in 2023, then plunged by 68.15% to $16.3 million in 2024, then fell by 24.14% to $12.4 million in 2025, then decreased by 2.45% to $12.1 million in 2026.
• Business Quant data shows CRBU's Cash & Equivalents at $12.1 million in Q1 2026, $12.4 million in Q4 2025, and $11.1 million in Q3 2025.